Objective: To retrospectively review the safety and efficacy of ultrasound (US)-guided percutaneous microwave ablation (MWA) of bilateral renal cell carcinomas (BRCCs).
Patients and Methods: In this study, eight patients of BRCCs with 20 lesions seen from November 2012 to October 2018 were enrolled retrospectively. The patients were treated with US -guided percutaneous MWA and were followed up with contrast-enhanced US and computed tomography or magnetic resonance imaging.
Results: Technical success was achieved 20 tumors. The 18 lesions were performed to ablate 90%; 2 lesions were repeated because of detecting residual ablated tumor. Except six patients were noted fever, no severe complications occurred. The median follow-up time was 24 months (range 7–59 months). Among the eight patients, there was no local tumor recurrence in 6 of 8 completely ablated tumor lesions. One patient was retreated by MWA 6 months after ablation, and another was retreated after 19 months due to local tumor recurrence. No patients have obvious change of renal function and lost their life.
Conclusion: US-guided percutaneous MWA is a beneficial treatment for BRCC.


中文翻译：

---

超声引导下经皮微波消融双侧肾细胞癌：关注安全性和有效性


目的：回顾性评价超声（US）引导下经皮微波消融（MWA）治疗双侧肾细胞癌（BRCC）的安全性和有效性。
患者与方法：本研究回顾性纳入 2012 年 11 月至 2018 年 10 月间 8 例 BRCC 患者，20 个病灶。患者接受了超声引导下经皮 MWA 治疗，随后进行了对比增强超声和计算机断层扫描或磁共振成像。
结果：20个肿瘤取得了技术上的成功。18个病灶消融90%；由于检测到残留的消融肿瘤，重复了2个病灶。除6例出现发热外，均未出现严重并发症。中位随访时间为 24 个月（范围 7-59 个月）。8 例患者中，8 个完全消融的肿瘤病灶中有 6 个没有局部肿瘤复发。1例消融6个月后MWA复治，19个月后因局部肿瘤复发复治。无患者出现肾功能明显改变而失去生命。
结论：超声引导下经皮 MWA 治疗 BRCC 是一种有益的治疗方法。